Metastasectomy in kidney cancer

A recent review published in Current Opinion in Supportive and Palliative Care this month has shown that although medicines for the treatment of metastatic renal cell carcinoma (RCC) have improved patient survival, remission and cure of the cancer is rare with medicines alone. In this review, the researchers look at outcomes following nephrectomy and surgical […]

read more

ESMO 2021: Sarcomatoid and/or rhabdoid RCC treated with immune checkpoint inhibitors after surgery

Cytoreductive nephrectomy is the surgical removal of the tumour to reduce the number of cancer cells (tumour burden), reduce the symptoms and immunosuppression caused by the tumour, and prevent complications. Recent studies have questioned the role of cytoreductive nephrectomy for patients with RCC that has spread (metastatic RCC). Metastatic sarcomatoid/rhabdoid clear cell RCC is an aggressive type of RCC that responds […]

read more

Partial nephrectomy versus radical nephrectomy for low risk kidney cancer

This study looked at the survival of patients following partial nephrectomy versus radical nephrectomy for low-risk renal cell carcinoma (RCC). A total of 1995 patients were included in the study and 53% had partial nephrectomy. The size of the tumour, the grade of the tumour (how aggressive it was), the number of blood vessels supplying […]

read more

Stereotactic radiotherapy for metastatic kidney cancer patients on TKIs

This phase 2 study looked at the use of stereotactic radiotherapy to treat metastatic renal cell carcinoma (RCC) in patients where the cancer had spread and there were a small number of metastases. These patients were on a tyrosine kinase inhibitor as the first or second medicine for their cancer. The aim of the study […]

read more

Stereotactic radiotherapy for patients on TKIs

Stereotactic radiotherapy is a very precise method of radiotherapy that uses fewer doses of radiation than conventional radiotherapy. In this study of 37 patients with spread of their cancer (metastases) at a limited number of places in the body, the researchers looked at how stereotactic radiotherapy affected the outcomes of patients on tyrosine kinase inhibitors, […]

read more

3D modelling of kidney tumours

Surgeons use three-dimensional (3D) models to improve their understanding of the structure (anatomy) of the kidney. A recent trial published in European Urology Focus last month looked at how 3D modelling could help to predict surgical outcomes after robot-assisted partial nephrectomy. Sixty-nine patients with small renal mass (T1-T2) who were scheduled to have robot-assisted partial […]

read more

Stereotactic radiotherapy with immunotherapy or targeted therapy for metastatic kidney cancer

This study looked at the safety and effectiveness of targeted therapies or immune checkpoint inhibitors (immunotherapy) in combination with stereotactic radiotherapy in patients with renal cell carcinoma (RCC). There were 53 patients in the study, of whom 32% were treated with immunotherapy and 68% targeted therapy. About a third of patients on targeted therapy paused […]

read more

Positive margins after partial nephrectomy and risk of recurrence in kidney cancer

In this meta-analysis, the results from 101,153 patients with renal cell carcinoma (RCC) from 42 studies were assessed for the risk of recurrence in patients with positive margins after partial nephrectomy (nephron-sparing surgery). The analysis showed that a positive surgical margin was associated with an increased risk of local recurrence (high certainty), metastasis (moderate certainty), […]

read more

Percutaneous microwave ablation of small renal masses

Percutaneous microwave ablation uses thin needle-like electrodes that are passed through the skin (percutaneous) into the tumour to kill the cancer cells with microwaves. This is usually done under the guidance of ultrasound imaging. During this observational study the short- and long-term outcomes of 113 patients who had microwave ablation for small renal masses (stage […]

read more

Delay in surgery and overall survival in patients with T2 renal masses

In a recent study of 11,848 patients who had surgery for stage T2 renal cell carcinoma (RCC), the researchers looked at the effect of a delay in having surgery on overall survival. The data were taken from the National Cancer Database. The study showed that patients who had a delay of 5 to 6 months […]

read more
Showing 1 to 10 of 68 results
  TOP